RT-PCR tyrosinase expression in the peripheral blood of melanoma patients

Expert Review of Molecular Diagnostics

Volumn 4, Issue 5, 2004, Pages 727-741

  Quaglino, Pietro ^a   Savoia, Paola ^a   Osella Abate, Simona ^a   Bernengo, Maria Grazia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Biologic markers; Melanoma follow up; Melanoma prognosis; Peripheral blood; RT PCR; Tyrosinase mRNA

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; MONOPHENOL MONOOXYGENASE;

BLOOD FLOW; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME ANALYSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PERIPHERAL CIRCULATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MODELS, CHEMICAL; MONOPHENOL MONOOXYGENASE; NEOPLASM METASTASIS; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 4544353593     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.4.5.727     Document Type: Review

References (101)

1. Ferlay J, Black RJ, Pisani P et al. EUCAN90: cancer in the European Union. Electronic database with graphic display. IARC Cancer Base No. 1. International Agency for Research on Cancer, Lyon, France (1996).
2. Parkin DM, Pisani P, Ferky J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80, 827-841 (1999).
3. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma: analysis of 186 patients. Ann. Surg. 212, 173-177 (1990).
4. Levy E, Silverman MK, Vossaert KA et al. Late recurrence of malignant melanoma: a report of five cases, a review of the literature and a study of associated factors. Melanoma Res. 1, 63-67 (1991).
5. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 15, 2361-2370 (1997).
6. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338, 1227-1229 (1991).
7. Hanekom GS, Johnson CA, Kidson SH. An improved and combined reverse transcription-polymerase chain reaction assay for reliable detection of metastatic melanoma cells in peripheral blood. Melanoma Res. 7, 111-116 (1997).
8. Hearing VJ, Jimenez M. Analysis of mammalian pigmentation at the molecular level. Pigment Cell Res. 2, 75-85 (1989).
9. Battayani Z, Xerri L, Hassoun J, Bonerandi JJ, Grob JJ. Tyrosinase gene expression in human tissues. Pigment Cell Res. 6, 400-405 (1993).
10. Soong SJ, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J. Surg. 16, 191-195 (1992).
11. Garbe C, Buttner P, Bertz J et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 75, 2484-2491 (1995).
12. Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J. Surg. Oncol. 67(4), 228-233 (1998).
13. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin. Oncol. 19(16), 3622-3634 (2001).
14. Averbook BJ, Fu P, Rao JS, Mansour EG. A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center implications on the future of cancer staging. Surgery 132(4), 589-604 (2002).
15. McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg. Gynecol. Obstet. 166(6), 497-502 (1988).
16. Slingluff CL Jr, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer 70(7), 1917-1927 (1992).
17. Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast. Reconstr. Surg. 91(1), 94-98 (1993).
18. Meier F, Will S, Ellwanger U et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br. J. Dermatol. 147(1), 62-70 (2002).
19. Garbe C, Paul A, Kohler-Spath H et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J. Clin. Oncol. 21(3), 520-529 (2003).
20. Kelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J. Am. Acad. Dermatol. 13 (5 Pt 1), 756-760 (1985).
21. Martini L, Brandani P, Chiarugi C, Reali UM. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow-up schedule. Tumori. 80(3), 188-197 (1994).
22. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol. 38(5), 549-557 (1999).
23. Dicker TJ, Kavanagh GM, Herd RM et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br. J. Dermatol. 140(2), 249-254 (1999).
24. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19, 3635-3648 (2001).
25. Kim CJ, Reintgen DS, Balch CM. AJCC Melanoma Staging Committee. The new melanoma staging system. Cancer Control 9, 9-15 (2002).
26. NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA 268(10), 1314-1319 (1992).
27. Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in stage I cutaneous malignant melanoma: an audit. Clin. Oncol. (R. Coll. Radiol.) 5(3), 174-180 (1993).
28. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 274(21), 1703-1705 (1995).
29. Poo-Hwu WJ, Ariyan S, Lamb L et al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 86(11), 2252-2258 (1999).
30. Sober AJ, Chuang TY, Duvic M et al. Guidelines/outcomes Committee. Guidelines of care for primary cutaneous melanoma. J. Am. Acad. Dermatol. 45(4), 579-586 (2001).
31. Slominski A, Carlson J, Worrsman J, Mihm MCJ. The role of molecular biology in diagnostic pathology of melanoma. Meth. Mol. Medicine 61, 123-163 (2001).
32. Slominski A. Coming of age of melanogenesis-related proteins. Arch. Pathol. Lab. Med. 126(7), 775-777 (2002).
33. Li W, Stall A, Shivers SC et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann. Surg. 231, 795-803 (2000).
34. Osella-Abate S, Savoia P, Cambieri I, Salomone B, Quaglino P, Bernengo MG. Role of RT-PCR tyrosinase detection in the monitoring of patients with advanced metastatic melanoma. Melanoma Res. 10(6), 545-555 (2000).
35. Blaheta HJ, Paul T, Sotlar K et al. Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumor thickness. Br. J. Dermatol. 145(2), 195-202 (2001).
36. Beaty MW, Fetsch P, Wilder AM, Marincola F, Abati A. Effusion cytology of malignant melanoma. A morphologic and immunocytochemical analysis including application of the MART-1 antibody. Cancer 81(1), 57-63 (1997).
37. Hoon DS, Kuo CT, Wascher RA et al. Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients. J. Invest. Dermatol. 117(2), 375-378 (2001).
38. Battayani Z, Grob JJ, Xerri L et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patient with melanoma. Arch. Dermatol. 131, 443-447 (1995).
39. Foss A, Guille M, Occleston NL, Hykin PG, Hungerford JL, Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription- polymerase chain reaction. Br. J. Cancer 72, 155-159 (1995).
40. Jung FA, Buzaid AC, Ross MI et al. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J. Clin. Oncol. 15(8), 2826-2831 (1997).
41. Alao JP, Mohamed MQ, Slade MJ, Retsas S. Detection of tyrosinase mRNA by RT-PCR in the peripheral blood of patients with advanced metastatic melanoma. Melanoma Res. 9, 395-399 (1999).
42. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Mohler T, Hunstein W. Hematogenous spread of malignant melanoma cells in different stages of disease. J. Invest. Dermatol. 101, 887-889 (1993).
43. Brossart P, Schmier JW, Kruger S et al. A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res. 55, 4065-4068 (1995).
44. Kunter U, Buer J, Probst M et al. Peripheral blood tyrosinase messanger RNA detection and survival in malignant melanoma. J. Natl Cancer Inst. 88, 590-594 (1996).
45. Pittman K, Burchill S, Smith B et al. Reverse transcriptase-polymerase chain reaction for the expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann. Oncol. 7, 297-301 (1996).
46. Carrillo E, Marchal JA, Prados J et al. Optimization of the tyrosinase mRNA probe to detect circulating melanocytes with reverse transcription and polymerase chain reaction. Cell. Mol. Biol. (Noisy-legrand) 44(8), 1247-1252 (1998).
47. Palmieri G, Strazzullo M, Ascierto PA, Satriano SM, Daponte A, Castello G. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Co-operative Group. J. Clin. Oncol. 17(1), 304-311 (1999).
48. Palmieri G, Ascierto PA, Perrone F et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J. Clin. Oncol. 21(5), 767-773 (2003).
49. Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment and recurrence from melanoma. J. Clin. Oncol. 16, 1760-1769 (1998).
50. Farthmann B, Eberle J, Krasagakis K et al. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J. Invest. Dermatol. 110(3), 263-267 (1998).
51. Mellado B, Gutierrez L, Castel T et al. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-porymerase chain reaction in long-term clinically disease-free melanoma patients. Clin. Cancer Res. 5(7), 1843-1848 (1999).
52. Gogas H, Kefala G, Bafaloukos D et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br. J. Cancer 87(2), 181-186 (2002).
53. Mellado B, Del Carmen Vela M, et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J. Clin. Oncol. 20(19), 4032-4039 (2002).
54. Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Bernengo MG. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res. 12(4), 325-334 (2002).
55. Osella-Abate S, Savoia P, Quaglino P et al. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br. J. Cancer 89(8), 1457-1462 (2003).
56. Hoon DS, Wang Y, Dale PS et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J. Clin. Oncol. 13, 2109-2116 (1995).
57. Mellado B, Colomer D, Castel T et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J. Clin. Oncol. 14, 2091-2097 (1996).
58. Ghossein RA, Coit D, Brennan M et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin. Cancer Res. 4, 419-428 (1998).
59. Glaser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J. Clin. Oncol. 15, 2818-2825 (1997).
60. Reinhold U, Ludtke-Handjery HC, Schnautz S, Kreysel HW, Abken H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J. Invest. Dermatol. 108(2), 166-169 (1997).
61. Tessier MH, Denis MG, Lustenberger P, Dreno B. Detection of circulating neoplastic cells by reverse transcriptase and polymerase chain reaction in melanoma. Ann. Dermatol. Venereol. 124(9), 607-611 (1997).
62. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J. Clin. Oncol. 17(8), 2562-2571 (1999).
63. Hanekom GS, Stubbings HM, Johnson CA, Kidson SH. The detection of circulating melanoma cells correlates with tumor thickness and ulceration but is not predictive of metastasis for patients with primary melanoma. Melanoma Res. 9(5), 465-473 (1999).
64. Schittek B, Bodingbauer Y, Ellwanger U, Blaheta HJ, Garbe C. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Br. J. Dermatol. 141(1), 30-36 (1999).
65. Reinhold U, Berkin C, Bosserhoff AK et al. Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: a multicenter study of the Dermatologic Cooperative Oncology Group. J. Clin. Oncol. 19(6), 1723-1727 (2001).
66. Warr RP, Zebedee Z, Kenealy J, Rigby H, Kemshead JT. The detection of tyrosinase mRNA in peripheral blood samples is unlikely to aid in the management of patients with localized malignant melanoma. Br. J. Plast. Surg. 56(6), 540-545 (2003).
67. Brownbridge GG, Gold J, Edward M, MacKie RM. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled- polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br. J. Dermatol. 144(2), 279-287 (2001).
68. Garbe C, Leiter U, Ellwanger U et al. Diagnostic value and prognostic significance of protein S-100β, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97(7), 1737-1745 (2003).
69. Reynolds SR, Albrecht J, Shapiro RL et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin. Cancer Res. 9(4), 1497-1502 (2003).
70. Szenajch J, Jasinski B, Synowiec A et al. Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma. Clin. Chem. 49(9), 1450-1457 (2003).
71. Wascher RA, Morton DL, Kuo C et al. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J. Clin. Oncol. 21(13), 2558-2563 (2003).
72. Fryer JP, Oetting WS, Brott MJ, King RA. Alternative splicing of the tyrosinase gene transcript in normal human melanocytes and lymphocytes. J. Invest. Dermatol. 117(5), 1261-1265(2001).
73. Denis MG, Masson D, Tessier MH et al. Sampling and the detection of melanoma cells in blood. Melanoma Res. 12(3), 291-292 (2002).
74. Szenajch J, Jasinski B, Kozak A et al. Multiple RT-PCR tyrosinase testing reveals that melanoma cells circulate in the blood of melanoma patients at the frequency more than 10 times below the detection threshold. Melanoma Res. 12(4), 399-401 (2002).
75. Berteau P, Dumas F, Gala JL et al. Influence of blood storage and sample processing on molecular detection of circulating prostate cells in cancer. Clin. Chem. 44(3), 677-679 (1998).
76. Chen YT, Stockert E, Tsang S, Coplan KA, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc. Natl Acad. Sci. USA 92, 8125-8129 (1995).
77. Eton O, Legha SS, Moon TE et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J. Clin. Oncol. 16(3), 1103-1111 (1998).
78. Zimmer DB, Cornwall EH, Landar A, Song W. The S-100 protein family: history, function, and expression. Brain Res. Bull. 37(4), 417-429 (1995).
79. Cho KH, Hashimoto K, Taniguchi Y, Pietruk T, Zarbo RJ, An T. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 66(4), 765-771 (1990).
80. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100β protein in malignant melanoma. Br. J. Dermatol. 138(3), 426-430 (1998).
81. Kaskel P, Berking C, Sander S, Volkenandt M, Peter RU, Krahn G. S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma. J. Am. Acad. Dermatol. 41(6), 962-969 (1999).
82. Jury CS, McAllister EJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br. J. Dermatol. 143(2), 269-274 (2000).
83. Henze G, Dummer R, Joller-Jemelka HI, Boni R, Burg G. Serum S100 - a marker for disease monitoring in metastatic melanoma. Dermatology 194(3), 208-212 (1997).
84. Hauschild A, Engel G, Brenner W et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br. J. Dermatol. 140(6), 1065-1071 (1999).
85. Apfel R, Lottspeich F, Hoppe J, Behl C, Durr G, Bogdahn U. Purification and analysis of growth regulating proteins secreted by a human melanoma cell line. Melanoma Res. 2(5-6), 327-336 (1992).
86. Faries MB, Gupta RK, Ye X, Hsueh EC, Morton DL. Melanoma-inhibiting activity assay predicts survival in patients receiving a therapeutic cancer vaccine after complete resection of American Joint Committee on Cancer Stage III Melanoma. Ann. Surg. Oncol. 11(1), 85-93 (2004).
87. Klimek VM, Williams L, Chapman PB. Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients. Cytokines Cell. Mol. Ther. 7(2), 71-74 (2002).
88. Kaiser E, Kuzmits R, Pregant P, Burghuber O, Worofka W. Clinical biochemistry of neurone specific enolase. Clin. Chim. Acta 183(1), 13-31 (1989).
89. Wibe E, Hannisdal E, Paus E, Aamdal S. Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma. Eur. J. Cancer 28A(10), 1692-1695 (1992).
90. Buzaid AC, Sandler AB, Hayden CL et al. Neuron-specific enolase as a tumor marker in metastatic melanoma. Am. J. Clin. Oncol. 17(5), 430-431 (1994).
91. Reintgen DS, Cruse CW, Wells KE, Saba HI, Fabri PJ. The evaluation of putative tumor markers for malignant melanoma. Ann. Plast. Surg. 28, 55-59 (1992).
92. Miliotes G, Lyman GH, Cruse CW et al. Evaluation of new putative tumor markers for melanoma. Ann. Surg. Oncol. 3, 558-563 (1996).
93. Land EJ, Riley PA. Spontaneous redox reactions of dopaquinone and the balance between the eumelanic and phaeomelanic pathways. Pigment Cell Res. 13(4), 273-277 (2000).
94. Karnell R, Kagedal B, Lindholm C, Nilsson B, Arstrand K, Ringborg U. The value of cisteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res. 10(4), 363-369 (2000).
95. Wakamatsu K, Yokochi M, Naito A, Kageshita T, Ito S. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients. Melanoma. Res. 13(4), 357-363 (2003).
96. Hirai S, Kageshita T, Kimura T. Serum levels of sICAM-I and 5-S-cysteinyldopa as marker of melanoma progression. Melanoma Res. 7, 58-62 (1997).
97. Sarantou T, Chi DD, Garrison DA et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res. 57(7), 1371-1376 (1997).
98. Schrader AJ, Probst-Kepper M, Grosse J et al. Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res. 10(4), 355-362 (2000).
99. Hoon DS, Bostick P, Kuo C et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60(8), 2253-2257 (2000).
100. Curry BJ, Myers K, Hersey P. Utility of tests for circulating melanoma cells in identifying patients who develop recurrent melanoma. Recent Results Cancer Res. 158, 211-230 (2001).
101. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Bonden EC, Blum RH. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Co-operative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1), 7-17 (1996).